Mereo BioPharma Group Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	0.5	-	10	-	49.37	-
Cost of Revenue	0.13	-	2.57	-1.15	24.25	-
Gross Profit	0.37	-	7.43	1.15	25.13	-
Selling, General & Admin	25.27	26.43	18.42	26.11	21.57	28.97
Research & Development	20.44	19.28	16.14	27.74	31.9	22.32
Operating Expenses	45.71	45.72	34.56	53.84	53.47	51.29
Operating Income	-45.34	-45.72	-27.14	-52.7	-28.35	-51.29
Interest Expense	-0.61	-1.37	-2.88	-4.18	-5.11	-8.5
Interest & Investment Income	2.63	3.04	2.13	0.84	0	0.01
Currency Exchange Gain (Loss)	0.77	1.21	-2.35	2.72	-1.29	-2.49
Other Non Operating Income (Expenses)	0.67	-0.42	0.24	10.37	53.88	-150.19
EBT Excluding Unusual Items	-41.87	-43.25	-30	-42.94	19.13	-212.46
Gain (Loss) on Sale of Investments	-	-	-	-	-	0.05
Gain (Loss) on Sale of Assets	-	-	-	-	0.15	-14.84
Pretax Income	-41.57	-43.25	-30	-42.94	19.28	-227.25
Income Tax Expense	-	-	-0.53	-0.72	2.05	-3.85
Net Income	-41.57	-43.25	-29.47	-42.22	17.23	-223.4
Net Income to Common	-41.57	-43.25	-29.47	-42.22	17.23	-223.4
Shares Outstanding (Basic)	158	148	132	121	106	68
Shares Outstanding (Diluted)	158	148	132	121	111	68
Shares Change (YoY)	9.71%	12.16%	9.33%	8.63%	63.82%	279.04%
EPS (Basic)	-0.26	-0.29	-0.22	-0.35	0.16	-3.30
EPS (Diluted)	-0.26	-0.29	-0.22	-0.35	-0.31	-3.30
Free Cash Flow	-32.73	-32.83	-21.13	-48.83	-7.82	-38.72
Free Cash Flow Per Share	-0.21	-0.22	-0.16	-0.41	-0.07	-0.57
Gross Margin	73.40%	-	74.26%	-	50.89%	-
Operating Margin	-9067.80%	-	-271.36%	-	-57.42%	-
Profit Margin	-8314.60%	-	-294.66%	-	34.90%	-
Free Cash Flow Margin	-6545.80%	-	-211.32%	-	-15.83%	-
EBITDA	-45.03	-45.13	-26.57	-52.52	-28.25	-49.11
EBITDA Margin	-	-	-265.70%	-	-57.22%	-
D&A For EBITDA	0.31	0.58	0.57	0.18	0.1	2.18
EBIT	-45.34	-45.72	-27.14	-52.7	-28.35	-51.29
EBIT Margin	-	-	-271.36%	-	-57.42%	-
Effective Tax Rate	-	-	-	-	10.64%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.